Research programme: siRNA hepatitis therapeutics - Alnylam Pharmaceuticals

Drug Profile

Research programme: siRNA hepatitis therapeutics - Alnylam Pharmaceuticals

Alternative Names: Sirna-034; Sirna-AV34

Latest Information Update: 16 May 2014

Price : $50

At a glance

  • Originator Sirna Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 06 Mar 2014 Alnylam Pharmaceuticals acquires Sirna Therapeutics
  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 22 Jun 2005 Preclinical data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Viral infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top